Sativa Group PLC (LON:SATI) said it has become a member of the Association for the Cannabinoid Industry (ACI) novel food consortium and its landmark toxicology study as part of what it said is its “ongoing commitment to continually deliver the highest level of regulatory compliance and substantiate ‘CBD you can trust'”.
The cannabidiol (CBD) products group said the toxicology study will provide safety data required for novel food dossiers validated by the UK’s Food Standards Agency (FSA) to remain on the market after March 31, 2021.
Sativa said its team of scientists and quality & compliance professionals in the UK and Poland have worked with the ACI to ensure its products meet quality management criteria.
As part of the process, the raw CBD ingredients and final products are tested by a third-party laboratory and cultivation, extraction and manufacturing processes and standards are scrutinised to ensure that Sativa is meeting safety and regulatory standards from the seed stage to the store shelf.
Sativa also said it is submitting its own novel food application for its portfolio of products on behalf of white label customers.
“At Sativa, producing the highest quality and compliant products is our number one objective! We welcome the FSA Novel Foods accreditation process and are very pleased to be associated with the ACI In our compliance efforts”, Sativa chief executive Henry Lees-Buckley said in a statement.